Annals of Hematology

, 88:855 | Cite as

The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience

  • Francesca Olcese
  • Marino Clavio
  • Edoardo Rossi
  • Mauro Spriano
  • Filippo Ballerini
  • Letizia Canepa
  • Ivana Pierri
  • Sara Aquino
  • Riccardo Varaldo
  • Annunziata Manna
  • Vincenzo Secondo
  • Omar Racchi
  • Enrico Balleari
  • Giulio Fraternali Orcioni
  • Angelo Michele Carella
  • Riccardo Ghio
  • Marco Gobbi
Original Article

Abstract

We retrospectively reviewed 139 stage I–II HL patients who were diagnosed and followed up in an Italian northern region (Liguria) from 1995 to 2007, and who received either chemotherapy (CT) alone (mainly doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVD) or a combined modality treatment (chemotherapy + radiotherapy, CT + RT). The two therapeutic groups were comparable for clinical and histologic features. Complete remission rate after CT + RT was higher than what was achieved with CT alone (96% vs. 84%, respectively, p = 0.03). Relapse rate (12%) was the same in both groups and disease-free survival curves were comparable (82% and 83%, p = 0.47). The overall survival of the two therapeutic groups is comparable. No second tumors have been reported among patients receiving chemotherapy alone, whereas a second neoplasia has been diagnosed in four patients (in two cases possibly radiotherapy related) in the CT + RT group (5%, p = 0.09) In conclusion, our retrospective study shows that CT + limited RT is an effective and well-tolerated option for early stage Hodgkin’s lymphoma, even if the use of RT is associated with a certain risk of developing a second tumor. However, four to six courses of ABVD can lead to similar, optimal, long-term disease control without exposing patients to the risk of a second neoplasia.

Keywords

Hodgkin’s lymphoma ABVD Radiotherapy Late toxicity Early stage 

References

  1. 1.
    Diehl V (2007) Hodgkin’s disease, from pathology specimen to cure. N Engl J Med 357:1968–1971PubMedCrossRefGoogle Scholar
  2. 2.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. N Engl J Med 339:1506–1514PubMedCrossRefGoogle Scholar
  3. 3.
    Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484PubMedGoogle Scholar
  4. 4.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614PubMedCrossRefGoogle Scholar
  5. 5.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Intergruppo Italiano Linfomi et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198–9207PubMedCrossRefGoogle Scholar
  6. 6.
    Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. Standard and increased-dose BEACOPP. N Eng J Med 348:2386–2395CrossRefGoogle Scholar
  7. 7.
    Diehl V, Fuchs M (2007) Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 18(Suppl 9):71–79Google Scholar
  8. 8.
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 22:2835–2841PubMedCrossRefGoogle Scholar
  9. 9.
    Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO et al (2006) Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin’s disease: cure balanced against complications. J Clin Oncol 24:605–611PubMedCrossRefGoogle Scholar
  10. 10.
    Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 25:3495–3502PubMedCrossRefGoogle Scholar
  11. 11.
    Fermè C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. EORTC-GELA H8 Trial. N Engl J Med 357:1916–1927PubMedCrossRefGoogle Scholar
  12. 12.
    Olweny CL, Ziegler JL (2008) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 358:742–759PubMedCrossRefGoogle Scholar
  13. 13.
    Hoppe RT (1997) Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115–118PubMedCrossRefGoogle Scholar
  14. 14.
    Ghalibafian M, Beaudre A, Girinsky T (2008) Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk. Radiother Oncol 87:82–88PubMedCrossRefGoogle Scholar
  15. 15.
    Travis LB (2007) Evaluation of the risk of therapy-associated complications in survivors of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:192–196Google Scholar
  16. 16.
    Kwong A, Hancock SL, Bloom JR, Pal S, Birdwell RL, Mariscal C et al (2008) Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin’s disease. Breast J 14:39–48PubMedCrossRefGoogle Scholar
  17. 17.
    Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586PubMedCrossRefGoogle Scholar
  18. 18.
    Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK Pai SK et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need. J Clin Oncol 22:62–68PubMedCrossRefGoogle Scholar
  19. 19.
    Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489PubMedCrossRefGoogle Scholar
  20. 20.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642PubMedCrossRefGoogle Scholar
  21. 21.
    Gospodarowicz MK, Meyer RM (2006) The management of patients with limited-stage classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:253–258Google Scholar
  22. 22.
    Jaffe ES, Lee Harris N, Stein H, Vardiman JW (2001) World Health Organization Classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  23. 23.
    Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A et al (2008) German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434–439PubMedCrossRefGoogle Scholar
  24. 24.
    Eich HT, Müller RP (2007) Current role and future developments of radiotherapy in early-stage favourable Hodgkin’s lymphoma. Strahlenther Onkol 183:16–18PubMedCrossRefGoogle Scholar
  25. 25.
    Hoppe RT (2007) Hodgkin’s lymphoma: the role of radiation in the modern combined strategies of treatment. Hematol Oncol Clin North Am 21:915–927PubMedCrossRefGoogle Scholar
  26. 26.
    Macdonald DA, Connors JM (2007) New strategies for the treatment of early stages of Hodgkin’s lymphoma. Hematol Oncol Clin North Am 21:871–880PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Francesca Olcese
    • 1
  • Marino Clavio
    • 1
  • Edoardo Rossi
    • 1
  • Mauro Spriano
    • 1
  • Filippo Ballerini
    • 1
  • Letizia Canepa
    • 1
  • Ivana Pierri
    • 1
  • Sara Aquino
    • 1
  • Riccardo Varaldo
    • 1
  • Annunziata Manna
    • 2
  • Vincenzo Secondo
    • 3
  • Omar Racchi
    • 4
  • Enrico Balleari
    • 1
  • Giulio Fraternali Orcioni
    • 5
  • Angelo Michele Carella
    • 1
  • Riccardo Ghio
    • 1
  • Marco Gobbi
    • 1
  1. 1.Department of Haematology and OncologyUniversity of Genova, San Martino HospitalGenovaItaly
  2. 2.Department of OncologyLa Spezia HospitalLa SpeziaItaly
  3. 3.Department of Internal MedicineGalliera HospitalGenovaItaly
  4. 4.Department of OncologyVilla Scassi HospitalGenovaItaly
  5. 5.Hemopathology ServiceUniversity of Genova, San Martino HospitalGenovaItaly

Personalised recommendations